Rick Wanstall | Head of Finances |
Manuel Aivado | President & Chief Executive Officer |
Vojislav Vukovic | Chief Medical Officer |
Allen Annis | Head of Research |
Rob Andrew | William Blair |
Justin Zelin | Canaccord |
Jacques Villefranc | LifeSci Capital |
Ladies and gentlemen, thank you for standing by and welcome to the Aileron Therapeutics Third Quarter 2019 Financial and Operational update. At this time, all participants are in a listen only mode. There will be a presentation by the Aileron management team, followed by a question-and-answer session. I must advice you all, that the conference today is being recorded.
I'd like to turn the call over to Rick Wanstall, Head of Finances at Aileron Therapeutics.